Nephrocare Health Services Limited

Nephrocare Health Services Limited (NEPHROPLUS) is a small-cap Healthcare company valued at ₹6,164 crore operating in Healthcare Service Provider on the NSE and BSE.

Recent price move

Nephrocare Health Services Limited last traded at ₹619.05, modestly up 1.21% on the day.

Recent developments

On 2026-06-30, the company reported a net profit of ₹32 crore for the latest quarter, up 33.3% from ₹24 crore in the same quarter a year earlier. On 2026-06-30, the company also reported revenue of ₹282 crore, up 23.7% from ₹228 crore in the same quarter a year earlier. On 2026-06-30, the company's net profit margin was 7.7%, down 1.2 percentage points from 8.9% in the prior year.

Financial performance

The company's business is growing, with annual revenue rising 32.1% year-over-year and the latest quarter revenue up 23.7% compared to the same quarter a year earlier. However, the net profit margin narrowed 1.2 percentage points to 7.7%, and while net profit rose 14.9% annually, return on equity remained flat at 8.8%.

Valuation multiples

The stock trades at 73.0 times earnings, a premium to the Healthcare median of 32.0, 6.73 times book value.

Things to watch

The company is not paying out dividends despite repeated profits. The cost of borrowing seems high, and the stock is 2.9% below its 52-week high.

Where it stands

The company has shown strong revenue growth, with annual revenue rising 32.1% and the latest quarter revenue up 23.7% year-over-year. However, the net profit margin narrowed to 7.7%, and the stock is 2.9% below its 52-week high.

Summarised by DocStoX's model on 2026-09-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.